Results 41 to 50 of about 169,757 (284)

A rare case of melanosis of the hard palate mucosa in a patient with chronic myeloid leukemia [PDF]

, 2015
Imatinib Mesylate, also known as Gleevec or ST1-571, is a tyrosine-kinase inhibitor used as the gold standard medication for the chronic myeloid leukemia (CML); Imatinib has indeed deeply revolutionized the CML therapy allowing most patients to have a ...
Bosco, Daniela, Fantozzi, Paolo Junior, Palaia, Gaspare, Romeo, Umberto, Tenore, Gianluca   +4 more
core   +3 more sources

Curcumin inhibits in vitro and in vivo chronic myelogenous leukemia cells growth: a possible role for exosomal disposal of miR-21

OncoTarget, 2015
Exosomes are nanosize vesicles released from cancer cells containing microRNAs that can influence gene expression in target cells. Curcumin has been shown to exhibit antitumor activities in a wide spectrum of human cancer.
S. Taverna, M. Giallombardo, Marzia Pucci, A. Flugy, M. Manno, S. Raccosta, C. Rolfo, G. De Leo, R. Alessandro   +8 more
semanticscholar   +1 more source

Celecoxib inhibits proliferation and survival of chronic myelogeous leukemia (CML) cells via AMPK-dependent regulation of β-catenin and mTORC1/2. [PDF]

, 2016
CML is effectively treated with tyrosine kinase inhibitors (TKIs). However, the efficacy of these drugs is confined to the chronic phase of the disease and development of resistance to TKIs remains a pressing issue.
Calabretta, Bruno, Canonico, Pier Luigi, Condorelli, Fabrizio, De Dominici, Marco, Genazzani, Armando A, Gnemmi, Ilaria, Mariani, Samanta A., Minassi, Alberto, Minieri, Valentina, Riva, Beatrice, Salomoni, Paolo   +10 more
core   +2 more sources

Blocking programmed cell death 1 in combination with adoptive cytotoxic T-cell transfer eradicates chronic myelogenous leukemia stem cells

Leukemia, 2015
Blocking programmed cell death 1 in combination with adoptive cytotoxic T-cell transfer eradicates chronic myelogenous leukemia stem ...
C. Riether, T. Gschwend, Anne-Laure Huguenin, C. Schürch, A. Ochsenbein   +4 more
semanticscholar   +1 more source

Juvenile Chronic Myelogenous Leukemia [PDF]

American Journal of Clinical Pathology, 1996
Juvenile chronic myelogenous leukemia (JCML) is an aggressive myeloproliferative disorder of childhood that differs both clinically and pathologically from adult type, Philadelphia chromosome positive chronic myelogenous leukemia, and from the other myeloproliferative disorders that are more common in adulthood.
Robert P. Castleberry, Mary M. Zutter, Jay L. Hess, Peter D. Emanuel   +3 more
openaire   +2 more sources

Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival [PDF]

, 2012
Recent evidence suggests CML stem cells are insensitive to kinase inhibitors and responsible for minimal residual disease in treated patients. We investigated whether CML stem cells, in a transgenic mouse model of CML-like disease or derived from ...
Anderson, Ashley Hamilton, Bhatia, Bin Zhang, Branford, Carsten Müller-Tidow, Chen, Chomel, Chu, Copland, Corbin, Daley, Druker, Druker, Druker, Elaine K. Allan, Felsher, Franck E. Nicolini, G. Vignir Helgason, Gabert, Gorre, Gothert, Graham, Hamilton, Hayette, Holyoake, Hughes, Hurtz, Jiang, Jordan, Jordanides, Jorgensen, Konig, Konig, Konig, Koschmieder, Li, Lombardo, Lugo, Mirle Schemionek, Myssina, Notta, Pellicano, Ravi Bhatia, Samanta, Samanta, Schemionek, Scott, Shachaf, Shah, Sharma, Sharma, Sobrinho-Simoes, Steffen Koschmieder, Svetlana Myssina, Talpaz, Tessa L. Holyoake, Valerie G. Brunton, Wang, Weinstein, Weisberg, White   +61 more
core   +1 more source

The role of stem cell transplantation for chronic myelogenous leukemia in the 21st century.

Blood, 2015
The introduction of tyrosine kinase inhibitors (TKIs), a treatment of chronic myelogenous leukemia (CML), has largely replaced curative strategies based on allogeneic stem cell transplantation (SCT).
A. J. Barrett, S. Ito
semanticscholar   +1 more source

Management of imatinib-resistant CML patients [PDF]

, 2007
Imatinib has had marked impact on outcomes in chronic myelogenous leukemia (CML) patients for all stages of the disease and is endorsed by international treatment guidelines as the first line option.
Branford S, Burger H, Burgess MR, Cortes J, Crossman LC, Donato NJ, Druker BJ, Gambacorti-Passerini C, Giles F, Hochhaus A, Hughes TP, Iacobucci I, Kantarjian H, Lahaye T, Mahon FX, Melo JV, O'Hare T, Quintas-Cardama A, Rousselot P, Sleijfer S, Soverini S, Weisberg E   +21 more
core   +1 more source

Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib

Blood Cancer Journal, 2015
Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL -positive chronic myelogenous leukemia treated with ruxolitinib and ...
A. Zhou, E. Knoche, E. Engle, Daniel A. C. Fisher, S. Oh   +4 more
semanticscholar   +1 more source

A case of chronic myelogenous leukemia in pregnancy characterized by a complex translocation t(9;22;11)(q34;q11.2;q13)

Hematology Reports, 2011
The management of chronic myelogenous leukemia during pregnancy requires balancing the well-being of the mother with that of the fetus. We report a case of a 26-year-old lady who was diagnosed with chronic myelogenous leukemia (CML) at 15 weeks gestation
Surachit Kumar, Mariya Apostolova, Paul V. Woolley   +2 more
doaj   +1 more source